Clinical trial of iotrol for lumbar myelography.
Iotrol, a new nonionic, water-soluble, hexiodinated dimeric contrast medium for myelography, was used in clinical trials in 29 patients. The purpose of the study was to acquire information on local and general tolerance, distribution and excretion, and image quality. Preliminary results show that iotrol is well suited for lumbar and thoracolumbar myelography. Side effects observed with the use of iotrol were fewer and less severe than those reported with metrizamide. Iotrol is cleared from the cerebrospinal fluid and excreted by glomerular filtration within the same time range as other water-soluble contrast media.
D000328:Adult; D001100:Arachnoiditis / Q000000981:diagnostic imaging*; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D005260:Female; D006801:Humans; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging*; D007463:Iodobenzoates; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009192:Myelography / Q000379:methods*; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; C033300:iotrolan